An Exploration of the Dynamics of Hiv/Aids
An Exploration of the dynamics of HIV/AIDS. | People have unlimited needs and wants, but governments have limited resources. In the allocation of funds to any sector, the government faces competing interests. Money must be allocated for roads, public transportation, education as well as health care. Thus any government, seeking the people’s best interests would need to find a way to allocate resources that would be both efficient and equitable.
HIV is an epidemic that treatments to wipe out the human capital of any economy. The disease has the potential to cripple economies, reduce productivity, and increase social problems. There are two approaches that can be used to mitigate the effects of HIV/AIDS upon a population: prevention and treatment. Prevention can target sexual pathways, non sexual pathways, or make each sexual activity less likely to transmit the disease. Treatment involves the use of Anti-retroviral drugs (ARVs) to prevent the replication of HIV.
Global Overview
United Nations Joint HIV/ AIDS Programme (UNAIDS) estimated that in 2009, 33 million people were living with HIV, globally. This indicated a 27% increase from 26.2 million people in 1999.40 Out of the 15 million people living with HIV/ AIDS in low income countries, it is estimated that only 5.2 million have access to treatment.40 The increase in the accessibility of treatment has resulted in a 19% decrease in AIDS-related deaths between 2004 and 2009.40
Globally, in 2009, an estimated 2.6 million people were newly infected with HIV. This represents a 19% reduction from the 3.1 million people newly infected in 1999.40 Due to improvements and increases in the availability of treatment and anti retroviral medications the global number of annual AIDS-related deaths is steadily decreasing. It declined from 2.1 million in 2004 to an estimated 1.8 million in 2009.40
The absolute number of people living with HIV in the Caribbean is relatively small. UNAIDS estimated in 2009 that
HIV is an epidemic that treatments to wipe out the human capital of any economy. The disease has the potential to cripple economies, reduce productivity, and increase social problems. There are two approaches that can be used to mitigate the effects of HIV/AIDS upon a population: prevention and treatment. Prevention can target sexual pathways, non sexual pathways, or make each sexual activity less likely to transmit the disease. Treatment involves the use of Anti-retroviral drugs (ARVs) to prevent the replication of HIV.
Global Overview
United Nations Joint HIV/ AIDS Programme (UNAIDS) estimated that in 2009, 33 million people were living with HIV, globally. This indicated a 27% increase from 26.2 million people in 1999.40 Out of the 15 million people living with HIV/ AIDS in low income countries, it is estimated that only 5.2 million have access to treatment.40 The increase in the accessibility of treatment has resulted in a 19% decrease in AIDS-related deaths between 2004 and 2009.40
Globally, in 2009, an estimated 2.6 million people were newly infected with HIV. This represents a 19% reduction from the 3.1 million people newly infected in 1999.40 Due to improvements and increases in the availability of treatment and anti retroviral medications the global number of annual AIDS-related deaths is steadily decreasing. It declined from 2.1 million in 2004 to an estimated 1.8 million in 2009.40
The absolute number of people living with HIV in the Caribbean is relatively small. UNAIDS estimated in 2009 that
References: 1. Ainsworth, M., & Over, M. (1999). Confronting AIDS: Public priorities in a global epidemic (2nd ed.). Oxford: Oxford University Press. 2. Altman, L. (1982, June 06). Clue found on homosexuals´ pre-cancer syndrome. The New York Times. 3. Auvert B. et al (25 October 2005), “Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial”, PloS Medicine 2(11) 4 5. Busch MP, Kleinman SH, Nemo GJ. 2003, “Current and emerging infectious risks of blood transfusions.” JAMA. 2003 Feb;289(8): 959-62 [PubMed ID: 12597733] 6 7. Centers for Disease Control. “Current trends update on acquired immune deficiency syndrome (AIDS),” Morbidity & Mortality Weekly Report 31, 37 (September 24, 1982): 513-514. 8. Centers for Disease Control. “Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California,” Morbidity & Mortality Weekly Report 30, 25 (July 4, 1981): 305-308. 9. Centers for Disease Control. “Pneumocystis pneumonia—Los Angeles,” Morbidity & Mortality Weekly Report 30, 21 (June 5, 1981): 250-252. 10. Chin. J. (Ed.) Communicable Diseases Manual, 17th Edition. Washington, DC: American Public Health Association. 2000. 11. Connor et al, 1994, “Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group”, NEJM 331(18), 3 November 1994 12 13. Department of Health and Human Services (January 2005). "A Pocket Guide to Adult HIV/AIDS Treatment January 2005 edition" 14 18. Guay et al, 1999, “Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial”, The Lancet 354(9181), 4 September 1999 19 20. Ivers, Louise C., David Kendrick and Karen Doucette. 2005. “Efficacy of Antiretroviral Therapy Programs in Resource-Poor Settings: A Meta-analysis of the Published Literature.” Clinical Infectious Diseases. 41, pp. 217–24. 21. Joint United Nations Program on HIV/AIDS. 2005a. “Global Summary of the HIV and AIDS Epidemic in 2005.” Geneva: UNAIDS. 22. Liskin L. 1990, “Using mass media for HIV/AIDS prevention.” AIDS Care. 1990;2:419–20. 23 25. McKee N, Bertrand JT, Becker-Benton A. 2004, “Strategic Communication in the HIV/AIDS Epidemic.” New Delhi: SAGE Publications; 2004. 26. Myhre SL, Flora JA. 2000, “HIV/AIDS communication campaigns: progress and prospects.” Journal of Health Communication. 2000;5(Suppl):29–45. 27 28. Osmond, D.H. 1998, “Sexual Transmission of HIV. HIV In Site Knowledge Base Chapter.” University of California, San Francisco, 1998 29 30. Pan American Health Organisation. AIDS Surveillance in the Americas. Biannual Report, December 2001. Washington DC: PAHO, 2001. 31 32. Patterson BK, Landay A, Siegel JN, et al. 2002, “Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture”. Am J Pathol. 2002 Sep;161(3):867-73. 33 34. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. 1996, “The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.” N Engl J Med. 1996 Jun;334 (26): 1685-90 [PubMed ID: 8637512] 35 39. UNAIDS/WHO, 2008, “Epidemiological Fact Sheet on HIV and AIDS Trinidad and Tobago 2008 update” 40 41. UNGASS Country Progress Report- Trinidad and Tobago, 2010 42 43. Walmsley S., 2006. Update on Antiretroviral Treatment Failure and the Management of Treatment-Experienced HIV-Infected Patients: Optimizing Therapy for Patients with Multidrug-Resistant HIV. Insight Medical Communications Inc. 44. Wawer, Maria J. et al. 2005. “Rates of HIV-1 Transmission per Coital Act by Stage of HIV-1 Infection, in Rakai, Uganda.” Journal of Infectious Diseases. 191: 9, pp. 1403–9. 45. World Bank, Confronting AIDS: public priorities in a global epidemic. Washington: Oxford University Press, 1997 46 47. World Health Organization (2005). Interim WHO Clinical Staging of HIV/AIDS and HIV/AIDS Case Definitions for Surveillance: African region. World Health Organization ; 2005 48 49. The Republic of Trinidad and Tobago Five year National HIV/AIDS Strategic Plan, January 2004-December 2008, Office of the Prime Minister, 2003. 50. Cohen S. 2004. “Beyond slogans: lessons from Uganda’s experience with ABC and HIV/AIDS”. Reproductive Health Matters, 12(23):132-5 51 52. Theodore K. 2001. “HIV-AIDS in the Caribbean: Economic Issues-Impact and Investment Response”. CMH Working Paper Series, Paper No. WG1: 1 Appendix